Canada has become the world's second country to approve a generic version of Novo Nordisk's Ozempic weight-loss drug after the company failed to pay a C$250 (over ₹17,500) government fee. Novo was supposed to pay the fee to renew Ozempic's patent. However, according to industry leaders, Novo intentionally let the patent expire so its supplementary price cap would expire too.